Monitoring Conformational Changes in the Receptor Tyrosine Kinase EGFR

被引:1
|
作者
Becker, Christian [1 ]
Oecal, Sinan [2 ,3 ]
Nguyen, Hoang D. [2 ,4 ]
Trang Phan [2 ,4 ]
Keul, Marina [1 ]
Simard, Jeffrey R. [2 ,5 ]
Rauh, Daniel [1 ,2 ]
机构
[1] Tech Univ Dortmund, Fak Chem & Chem Biol, Otto Hahn Str 4a, D-44227 Dortmund, Germany
[2] Max Planck Inst Mol Physiol, Chem Genom Ctr, Otto Hahn Str 15, D-44227 Dortmund, Germany
[3] Univ Cologne, Dept Math & Nat Sci, Inst Biochem, Otto Fischer Str 12-14, D-50674 Cologne, Germany
[4] Vietnam Natl Univ Ho Chi Minh City, Univ Sci, 227 Nguyen van Cu Str Dist 5, Ho Chi Minh City, Vietnam
[5] Amgen Inc, 360 Binney St, Cambridge, MA 02142 USA
关键词
GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; INHIBITOR SELECTIVITY; DRUG-RESISTANCE; MUTATIONS; GEFITINIB; DOMAIN; ERLOTINIB; AZD9291; ACTIVATION;
D O I
10.1002/cbic.201600115
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The receptor tyrosine kinase EGFR is regulated by complex conformational changes, and this conformational control is disturbed in certain types of cancer. Many ligands are known to bind EGFR in its active conformation, thereby preventing ATP from binding. Only a few ligands are known to stabilize EGFR in its inactive conformation, thus providing novel strategies for perturbing EGFR activity. We report a direct binding assay that enables the identification of novel ligands that bind to and stabilize the inactive conformation of EGFR.
引用
收藏
页码:990 / 994
页数:5
相关论文
共 50 条
  • [41] Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
    Yu, Helena A.
    Sima, Camelia S.
    Huang, James
    Solomon, Stephen B.
    Rimner, Andreas
    Paik, Paul
    Pietanza, M. Catherine
    Azzoli, Christopher G.
    Rizvi, Naiyer A.
    Krug, Lee M.
    Miller, Vincent A.
    Kris, Mark G.
    Riely, Gregory J.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : 346 - 351
  • [42] Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
    El Guerrab, Abderrahim
    Bamdad, Mahchid
    Kwiatkowski, Fabrice
    Bignon, Yves-Jean
    Penault-Llorca, Frederique
    Aubel, Corinne
    ONCOTARGET, 2016, 7 (45) : 73618 - 73637
  • [43] Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI)
    Tseng, Yen-Han
    Hung, Hsiu-Ying
    Sung, Yi-Chen
    Tseng, Yen-Chiang
    Lee, Yu-Chin
    Whang-Peng, Jacqueline
    Chen, Yuh-Min
    JOURNAL OF CHEMOTHERAPY, 2016, 28 (01) : 50 - 58
  • [44] Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation
    Cho, Su-Hee
    Park, Lee Chun
    Ji, Jun Ho
    Park, Silvia
    Hwang, Deok Won
    Lee, Ji Yean
    Choi, Yoon-La
    Han, Jung-Ho
    Sun, Jong-Mu
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 315 - 320
  • [45] Characterization of acquired receptor tyrosine-kinase fusions as mechanisms of resistance to EGFR tyrosine-kinase inhibitors
    Xu, Haiyuan
    Shen, Jinge
    Xiang, Jianxing
    Li, Haiyan
    Li, Bing
    Zhang, Tengfei
    Zhang, Lu
    Mao, Xinru
    Jian, Hong
    Shu, Yongqian
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 6343 - 6350
  • [46] Mechanisms of resistance to EGFR tyrosine kinase inhibitors
    Huang, Lihua
    Fu, Liwu
    ACTA PHARMACEUTICA SINICA B, 2015, 5 (05) : 390 - 401
  • [47] Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
    Girard, Nicolas
    FUTURE ONCOLOGY, 2018, 14 (11) : 1117 - 1132
  • [48] Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC
    Pallis, A. G.
    Syrigos, K. N.
    LUNG CANCER, 2013, 80 (02) : 120 - 130
  • [49] Evolving Landscape of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Kao, Steven C.
    Boyer, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (27) : 3233 - 3234
  • [50] Clinical Predictors of Response to EGFR Tyrosine Kinase inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Fukihara, Jun
    Watanabe, Naohiro
    Taniguchi, Hiroyuki
    Kondoh, Yasuhiro
    Kimura, Tomoki
    Kataoka, Kensuke
    Matsuda, Toshiaki
    Yokoyama, Toshiki
    Hasegawa, Yoshinori
    ONCOLOGY, 2014, 86 (02) : 86 - 93